Press release archive 2002

Thursday, 19 December 2002
FDA ADVISORY COMMITTEE REQUESTS FURTHER DATA ON ASTRAZENECA’S CASODEX® (BICALUTAMIDE) 150 MG FOR EARLY PROSTATE CANCER AstraZeneca announced today that the Oncologic Drugs Advisory Committee (ODAC) to the U.S. Food and Drug Administration (FDA) did not recommend approval of the new indication for CASODEX 150 mg for the treatment of early stage prostate cancer. The panel recommendation does not impact on the current use and approval of CASODEX 50 mg formulation, and also does not impact on CASODEX 150 mg approvals in other countries.
Thursday, 12 December 2002
ASTRAZENECA WINS AUSTRALIA HIGH COURT APPEAL ON OMEPRAZOLE FORMULATION PATENT AstraZeneca today announced that the High Court of Australia has granted its appeal against an earlier Federal Court decision in a dispute with the generic pharmaceutical company, Alphapharm Pty Limited, about the validity of the formulation patent for omeprazole – the active substance used in Losec, a treatment for acid-related disorders, such as peptic ulcers.
Wednesday, 11 December 2002
LATEST UPDATES FROM GROUNDBREAKING ATAC TRIAL CONFIRMS SUPERIORITY OF ARIMIDEX® OVER TAMOXIFEN IN EARLY BREAST CANCER AstraZeneca today announced from the San Antonio Breast Cancer Symposium in Texas, that the latest updates from the ATAC ( A rimidex, T amoxifen A lone or in C ombination) trial confirm the superior efficacy and favourable tolerability profile of ARIMIDEX over tamoxifen seen in as seen in the results reported last year.
Monday, 9 December 2002
FIRST CHRONIC TREATMENT STUDY WITH ORAL EXANTA™ (XIMELAGATRAN) DEMONSTRATES HIGHLY SIGNIFICANT LONG TERM BENEFIT IN PREVENTING RECURRENT VENOUS THROMBOEMBOLISM (VTE) Additional data demonstrate superiority of EXANTA over both warfarin and enoxaparin in preventing VTE after major elective orthopaedic surgery
Friday, 6 December 2002
NEW DATA DEMONSTRATES SYMBICORT® IS AN EFFECTIVE NEW TREATMENT FOR MODERATE TO SEVERE COPD AstraZeneca announced today that new data from a 12 month study presented at the British Thoracic Society (BTS) show that SYMBICORT® TURBUHALER® markedly reduces exacerbations and improves lung function in patients with moderate to severe chronic obstructive pulmonary disease (COPD), making it an important new treatment for this serious disease.
Tuesday, 26 November 2002
ASTRAZENECA OPENS EAST ASIA CLINICAL RESEARCH CENTRE IN SHANGHAI AstraZeneca announced today the opening of its Clinical Research Unit-East Asia (ACRU-EA) in Shanghai.
Thursday, 21 November 2002
ASTRAZENECA APPOINTS NEW GROUP TREASURER Adrian Marsh will join AstraZeneca PLC, the international pharmaceuticals company, as Group Treasurer on January 1, 2003.
Thursday, 14 November 2002
ASTRAZENECA PLC – DIRECTORATE ANNOUNCEMENT AstraZeneca PLC today announced that Åke Stavling will be leaving the Company on 31 January 2003. Åke Stavling is 58 and has been an Executive Director since April 1999. He played a key role in the integration of Astra and Zeneca following the merger in 1999 and since then has been responsible for Business Development. From 1993-1999 he was Executive Vice President and Chief Financial Officer of Astra AB and before that held senior positions at Atlas Copco and Ericsson.
Thursday, 7 November 2002
ASTRAZENECA’S NEW STATIN, CRESTOR™, RECEIVES FIRST APPROVAL IN EUROPE - Other European markets should follow in 2003 AstraZeneca announced today it has received the first approval for CRESTOR™ (rosuvastatin) 10-40 mg from the Medicines Evaluation Board (MEB) in the Netherlands for the management of primary hypercholesterolaemia and mixed dyslipidaemia.
Thursday, 7 November 2002
ASTRAZENECA REPORTS SIGNIFICANT PROGRESS ACROSS ITS PROMISING RESEARCH AND DEVELOPMENT PORTFOLIO AstraZeneca today updated analysts on the company's late stage development products and projects; the progress of earlier stage products, notably in the cardio-vascular and oncology therapeutic areas; and the improved productivity in drug discovery, at its annual business review meeting in Alderley Park, Cheshire, UK, a centre of excellence for Oncology Research and Development at AstraZeneca.